Beyond weight loss: multisystem benefits of obesity medications.
Obesity medications, especially GLP-1 receptor agonists, may offer benefits beyond weight loss, but specific outcomes are not detailed.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpusSummary and findings
This review synthesizes evidence from randomized controlled trials and meta-analyses on obesity medications, including retatrutide. It evaluates the effects of these medications across various obesity-related conditions. The findings suggest that GLP-1-based therapies may have weight loss-independent benefits.
Abstract
Obesity is increasingly managed with medications as disease-modifying therapies, reflecting its role as a gateway disease driving metabolic, cardiovascular, reproductive, neuropsychiatric, and mechanical conditions. This Review synthesises evidence from randomised controlled trials and high-quality meta-analyses on approved and late-stage investigational obesity medications, including phentermine-topiramate, naltrexone-bupropion, glucagon-like peptide-1 (GLP-1) receptor agonists (eg, liraglutide, semaglutide, subcutaneously and orally), and newer GLP-1 receptor agonist-based agents (eg, tirzepatide, survodutide, mazdutide, retatrutide, cagrilintide-semaglutide, and amycretin). We evaluated the effects of obesity medications across major obesity-related conditions, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease, heart failure, cardiovascular disease, obstructive sleep apnoea syndrome, polycystic ovary syndrome (recently named polyendocrine metabolic ovarian syndrome), osteoarthritis, muscle mass, depression, quality of life, and food cravings, along with binge-eating disorders, substance use disorders, and neurodegenerative diseases. Overall, GLP-1-based and multiagonist therapies show beneficial effects across these comorbid conditions. While many benefits of obesity medications are mediated by weight loss, accumulating evidence indicates important weight loss-independent effects, particularly with GLP-1 receptor agonist-based therapies. A broader understanding of these pleiotropic effects is essential to inform personalised obesity management and optimise long-term clinical outcomes.
Background
The paper addresses the role of obesity medications as disease-modifying therapies due to obesity's impact on multiple health conditions. Prior literature has established that obesity is linked to metabolic and cardiovascular issues, but the review aims to highlight the broader effects of these medications. Understanding these effects is crucial for personalized obesity management.
Methods
The review synthesizes data from randomized controlled trials and high-quality meta-analyses. Specific study designs, populations, sample sizes, doses, and durations are not detailed in the abstract. It focuses on various obesity medications, including GLP-1 receptor agonists.
Results
Not reported in abstract.
Interpretation
The review suggests that while weight loss is a significant benefit of obesity medications, there are also important weight loss-independent effects, particularly with GLP-1 receptor agonists. However, without specific numeric findings, it is difficult to assess the clinical significance of these effects. The lack of detailed data limits the ability to draw strong conclusions regarding the implications for practice.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.